B+
Overall grade
B+
Financial quality
The sleeper story is Shield's margin inflection happening 2-3 quarters early, creating unexpected reinvestment capacity that management is deploying into commercial expansion rather than banking for cash flow improvement. The obvious headline is strong revenue guidance raise, but strip out the reimbursement tailwinds and one-time collections and this is more about payer mix optimization than fundamental demand acceleration. The binding constraint is sales force productivity on both Shield (200 reps by year-end from ~100 today) and Reveal surveillance adoption where management was notably vague despite the Medicare coverage win. Most revealing quote: 'We achieved positive gross margin for Shield in the first quarter, much sooner than we had originally anticipated' - they're ahead of their own internal plan. My view changes if Shield rep productivity metrics disappoint in Q2 or if Reveal surveillance adoption shows concrete monthly progression metrics rather than qualitative language.
The 30-second version
- The real story: Shield's gross margin inflection happening 2-3 quarters ahead of plan
- Oncology volume acceleration masks a concerning ASP dependency
- Reveal surveillance launch soft-pedaled despite Medicare coverage win
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Total Revenue | $202M (+30% YoY Q4) | $204M (+21% YoY Q1) |
| Oncology Revenue | $185M (+30% YoY) | $151M (+20% YoY) |
| Oncology Volume | 57,300 tests (+24% YoY) | 59,000 tests (+25% YoY) |
| Guardant360 ASP | ~$3,000 | $3,000-$3,100 |
| Biopharma Revenue | $39M (+15% YoY Q4) | $45M (+21% YoY Q1) |
| Shield Revenue | $4.1M Q4 | $5.7M Q1 |
| Shield Tests | 6,400 Q4 | 9,000 Q1 |
| Shield ASP | ~$600 Q4 | ~$600 Q1 |
Accountability tracked
7 new promises made5 narrative shifts flagged7 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →